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Abstract
In clinical practice, patients with anorexia nervosa (AN), their carers and clini-
cians often disagree about psychopharmacological treatment. We developed two
corresponding questionnaires to survey the perspectives of patients with AN and
their carers on psychopharmacological treatment. These questionnaires were dis-
tributed to 36 patients and 37 carers as a quality improvement project on a specialist
unit for eating disorders at the South London and Maudsley NHS Foundation Trust.
Although most patients did not believe that medication could help with AN, the
majority thought that medication for AN should help with anxiety (61.1%), con-
centration (52.8%), sleep problems (52.8%) and anorexic thoughts (55.6%). Most of
the carers shared the view that drug treatment for AN should help with anxiety
(54%) and anorexic thoughts (64.8%). Most patients had concerns about potential
weight gain, increased appetite, changes in body shape and metabolism during
psychopharmacological treatment. By contrast, the majority of carers were not
concerned about these specific side effects. Some of the concerns expressed by the
patients seem to be AN-related. However, their desire for help with anxiety and
anorexic thoughts, which is shared by their carers, should be taken seriously by
clinicians when choosing a medication or planning psychopharmacological studies.
Keywords: anorexia nervosa, psychopharmacological treatment, treatment effects,
side effects, opinion survey, patients, carers
1. Introduction
1.1 Anorexia nervosa
Anorexia nervosa (AN) is an eating disorder. According to the 5th edition of the
Diagnostic and Statistical Manual of Mental Disorders (DSM-5) [1], its diagnostic
criteria are significantly low body weight, intense fear of weight gain, and disturbed
body perception. The prevalence of AN is up to 1% among women with a men-to-
women ratio of 1–10 [2]. The peak incidence is at an age between 14 and 17 years
[3]. The course is often chronic, and it can lead to persistent disability [4]. A recent
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longitudinal cohort study showed that only about 30% of patients with AN have
recovered after 9 years [5]. AN has also been reported to be associated with a
significantly increased mortality with a standardized mortality ratio (SMR) of 5.21
[6]. Thus, novel approaches such as psychopharmacological options should be con-
sidered to improve the treatment outcome and the care for people with AN.
1.2 Carers’ help for patients with anorexia nervosa
Family members, partners and friends are usually highly motivated to care for
patients with AN, but they are also often suffering. AN can make them feel guilty or
anxious which is neither justified nor helpful. Family therapy for AN can tackle
these feelings, can identify interpersonal difficulties maintaining the disorder, teach
psychosocial and communication skills, and thus enable the carers to help the
patients work towards recovery [7, 8]. The carers’ help may also include supporting
psychopharmacological treatment.
1.3 Psychopharmacological treatment for anorexia nervosa
The discovery of psychopharmacological treatment options in the 1950s led to a
massive breakthrough in the treatment of schizophrenia and depression. Patients
who previously had to live in asylums became enabled to lead a self-determined and
autonomous life with their families, and resume taking up employment [9]. Patients
with AN, however, did not benefit from this success, as the antipsychotics and
antidepressants developed did not prove to be effective in AN.
Psychiatric researchers have unsuccessfully tried for decades to apply these
medications to the treatment of AN, which is why there is no single medication
approved for use in AN [10]. Part of the problem is the difficulty in conducting
randomized controlled trials (RCTs) in AN. Most of these RCTs chose weight gain
as their main outcome criterion. However, this is what patients with AN fear, and
this fear is indeed a symptom of their disorder. Therefore, recruitment for psycho-
pharmacological studies in AN has been a significant challenge [11]. Despite these
obstacles, RCTs have been performed and published, although the recruitment rate
of these RCTs has been so low that the results may not be generalizable.
The lack of effective psychopharmacological treatment has left patients with AN
in a situation where clinical treatment outcomes are very modest. End-of-treatment
remission rates of RCTs in adult patients with AN range between 13 and 43% [12].
This is a sobering figure highlighting the pernicious nature of AN and its mortality
rate, which is—as already mentioned above—five to six times greater than in the
general population [6, 13, 14].
The biological mechanisms leading to AN are not completely understood.
Therefore, currently it is not possible to design a drug that would specifically target
the biological cause of this psychiatric disorder [10]. However, clinicians could
consider prescribing medication that targets certain symptoms which are important
or frequent in patients with AN.
1.4 The patients’ perspective
During the psychiatric history taking and examination, patients with AN often
report that they use self-starvation to cope with stress, difficulties and overwhelm-
ing emotions. Thus, AN could be seen as a strategy for coping with underlying
problems such as stress, anxiety or low mood [15]. Therefore, a medication that
induces appetite and increases weight could be perceived by patients with AN as a
way of re-exposing them to these underlying problems. Therefore, when drug
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treatment is considered, patients with AN are more interested in whether this
medication might help with certain psychological symptoms including anxiety,
mood, and problems with concentration and sleep [10, 16].
Weight gain can thus only be a first treatment step to reverse the acute effects of
starvation. Relying on weight outcomes alone in drawing conclusions from RCTs
could inflate the interpretation of positive results [14]. Instead, weight gain and
psychological improvement should be considered as important treatment outcomes
in their own right [14].
Psychopharmacological agents have potential side effects, including an increase
in appetite, weight gain, binge eating, alterations in metabolism, cardiac problems,
nausea, haematological changes, tiredness, mood changes and other psychological
effects. It is important to share these potential side effects with the patients when
obtaining their consent to treatment, as sharing this knowledge helps the process of
shared decision-making about a psychopharmacological treatment and contributes
to drug safety [17, 18].
1.5 The carers’ perspective
As carers can support their loved ones towards recovery [19], it makes sense to
involve them in medical and specifically psychopharmacological decisions. They
can support patients when they take their medication, and they can observe and
report beneficial and adverse effects. Thus, we surveyed the carers’ views and
expectations towards psychopharmacological treatment for AN. In this chapter, the
term ‘carer’ is used quite broadly. It can be anyone caring for a person with an
eating disorder, such as a parent, a sibling, a partner or a friend.
1.6 Aim of this study
This study was performed to survey the patients’ and carers’ perspectives of
psychopharmacological interventions targeting symptoms of AN. Therefore, a
questionnaire was developed to gather the patients’ views and another question-
naire, with questions of similar content, was developed to gather the carers’ views.
In this book chapter, we present both these questionnaires on the patients’ and the
carers’ views on psychopharmacological treatment for AN, and we report on the
statistical results of the survey.
2. Methods
2.1 Development of the questionnaires
In order to perform a quality improvement (QI) project in the Eating Disorders
Service of the South London and Maudsley NHS Foundation Trust (SLaM), we
developed a questionnaire for such a project. The QI project team consisted of
patients and psychiatrists from the eating disorders inpatient ward, the ‘step-up’
service (a day-hospital service) and the outpatient unit of SLaM. The questionnaire
has three main sections. The first section provides basic information on the patient
or the carer and their experience with medication prescribed to them or their loved
one respectively. The second section asks about what therapeutic effects a psycho-
pharmacological medication should have to help with symptoms of AN. The third
section is about concerns of potential side effects.
Initially, the questionnaires were distributed to a group of 17 patients with AN
and 16 carers between June 2016 and January 2017. The answers given were
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evaluated and the main results have been published in a scientific letter [16]. The
feedback received from SLaM patients, carers and colleagues suggested minor
alterations to the wording of a few questions and the addition of three further
questions. Therefore, we made these changes accordingly and distributed the ques-
tionnaires to a second cohort of 19 patients and 21 carers between March and
September 2018. Thus, taking both cohorts together, we obtained completed ques-
tionnaires from 36 patients and 37 carers.
The patient and the carer questionnaires used in the second cohort are depicted
in the appendix of this article.
2.2 Study sample
The total sample of people who completed the questionnaires included 36
patients and 37 carers.
Patients were all females between 18 and 44 years of age; mean age:
27.64 years  6.85 standard deviation (SD); seven were treated as outpatients, five
as day-patients and 24 as inpatients in our specialist unit at the time of the survey.
The duration of treatment ranged between 1 week and 15 years; mean duration of
treatment: 50.12 weeks  136.62 SD. The duration of their AN was between 1 year
and 24 years; mean 9.03 years  6.67 SD. Twenty-four of these patients were
currently receiving psychopharmacological treatment.
The carers were 21 males and 16 females between 21 and 71 years; mean age:
51.40 years  11.11 SD. Their close others with AN were two male and 35 female
patients between 18 and 44 years old, mean age: 24.62 years  6.71 SD. Of these
close others with AN, 12 were treated as outpatients, three as day-patients and 22 as
inpatients in our unit at the time of the survey. The duration of treatment of these
patients ranged from ‘not yet started’ to 52 weeks; mean duration of treatment:
11.60 weeks  12.20 SD. The duration of their AN was between 1 and 20 years;
mean 7.01 years  6.64 SD. A total of 27 of these patients were currently on
medication for mental health problems.
2.3 Data evaluation and statistics
The questionnaires were statistically evaluated using IBM SPSS statistics
version 24. We used descriptive statistics to evaluate the questionnaires.
For consistency, the additional questions in the new version of both the patients’
and the carers’ questionnaires were excluded from statistical evaluation. Thus, the
questions on appetite increase and improved gastrointestinal symptoms as poten-
tially desired effects of medication for AN were not included, nor was the question
about concerns of changes in the way of thinking as a potential side effect. The
evaluation of free text answers was not part of the current publication.
3. Results
3.1 Opinions about therapeutic effects of a medication for anorexia nervosa
Regarding the overall opinion on drug treatment for AN, most patients
disagreed in our survey with the view that medication could help with AN, whereas
the majority of carers were undecided in this regard. Approximately one third of
patients were also neutral about this. In terms of the question on whether patients
with AN should consider medication for treatment, a proportion of almost 40% of
patients and carers expressed no particular point of view. However, more than half
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of the carers believed that patients with AN should consider drug treatment. Most
of the patients agreed or strongly agreed with the statement that they did not want
medication for treatment with AN, whereas the carers had more diverse opinions in
this respect with 40% of neutral opinion and 65% of carers believing that medi-
cation should be taken if recommended. However, patients were more cautious
about this statement, with 42% expressing a neutral view on this.
The results revealed that 50% of patients agreed or strongly agreed with each
of the following target symptoms of psychopharmacological treatment: anxiety
(61.1%; sum of ‘agreed’ plus ‘strongly agreed’), concentration (52.8%), sleep prob-
lems (52.8%) and anorexic thoughts (55.6%). Most of the carers shared the view
that drug treatment should help with anxiety (54%) and anorexic thoughts
(64.8%).
In both patients and carers, 75% stated that more research on drug treatment
for AN is needed. As much as 40% of patients expressed their willingness to take
part in such research, and 25% of patients were undecided about whether they
should take part or not.
Detailed information on the frequencies and percentages of answers concerning
the therapeutic effects of a medication for the treatment of AN can be found in
Table 1.
3.2 Concerns about side effects of medication for anorexia nervosa
More than 90% of patients agreed or strongly agreed that they had concerns
about potential weight gain during psychopharmacological treatment, and about
the same number of patients also expressed concerns about appetite increase during
drug treatment. Furthermore, the majority of patients were afraid of binge eating,
changes in body shape and changes in metabolism.
Most of the patients were also concerned about potential side effects not related
to appetite or weight regulation. These included changes in mood, tiredness or
sleepiness, problems with the heart or the heart rhythm, nausea, decreased concen-
tration, changes in laboratory parameters and sleep problems.
By contrast, a majority of carers were not concerned about weight gain, appetite
increase, and changes in body shape nor metabolism. However, most of the carers
feared binge eating as a side effect and adverse effects related to mood, tiredness,
heart problems, nausea, concentration, laboratory parameters and sleep.
Detailed information on frequencies and percentages of answers concerning the
potential side effects of a medication for the treatment of AN can be found in
Table 2.
4. Discussion
4.1 Summary of findings
Taken together, we have developed questionnaires for patients with AN and for
carers to express their opinion on psychopharmacological treatment for AN. Most
patients did not think that medication could help with AN. However, the majority
of patients thought that medication for AN should help with anxiety, concentration,
sleep problems and anorexic thoughts. In this respect, most of the carers shared the
view that drug treatment for AN should help with anxiety and anorexic thoughts.
Almost all patients who participated in the survey had concerns about potential
weight gain and increased appetite during psychopharmacological treatment, and
most of them also feared changes in body shape and metabolism. The majority of
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Patients (N = 36) Carers (N = 37)
Frequency Percent (%) Frequency Percent (%)
Medication could help with anorexia nervosa
Strongly disagree 1 2.8 0 0
Disagree 18 50.0 1 2.7
Neutral 11 30.6 21 56.8
Agree 6 16.7 12 32.4
Strongly agree 0 0 2 5.4
Patients with anorexia nervosa should consider medication for treatment
Strongly disagree 3 8.3 0 0
Disagree 5 13.9 1 2.7
Neutral 14 38.9 14 37.8
Agree 12 33.3 20 54.1
Strongly agree 2 5.6 1 2.7
I do not want medication for anorexia nervosa
Strongly disagree 2 5.6 7 18.9
Disagree 8 22.2 8 21.6
Neutral 7 19.4 14 37.8
Agree 14 38.9 6 16.2
Strongly agree 5 13.9 1 2.7
Medication should be taken if recommended
Strongly disagree 1 2.8 0 0
Disagree 3 8.3 0 0
Neutral 15 41.7 10 27.0
Agree 16 44.4 24 64.9
Strongly agree 1 2.8 1 2.7
Medication should help with anxiety
Strongly disagree 2 5.6 0 0
Disagree 4 11.1 3 8.1
Neutral 8 22.2 11 29.7
Agree 16 44.4 17 45.9
Strongly agree 6 16.7 3 8.1
Medication should help with low mood
Strongly disagree 3 8.3 0 0
Disagree 7 19.4 3 8.1
Neutral 9 25.0 15 40.5
Agree 8 22.2 14 37.8
Strongly agree 9 25.0 3 8.1
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carers, in contrast, was not concerned about weight gain, appetite increase, changes
in body shape and metabolism. All the addressed side effects were of concern to
patients. For the carers, for most of the questions on side effects, between 20 and
40% of had no particular opinion and thus gave a neutral answer.
Patients (N = 36) Carers (N = 37)
Frequency Percent (%) Frequency Percent (%)
Medication should help to improve concentration
Strongly disagree 1 2.8 1 2.7
Disagree 9 25.0 6 16.2
Neutral 7 19.4 17 45.9
Agree 14 38.9 9 24.3
Strongly agree 5 13.9 2 5.4
Medication should help with sleep
Strongly disagree 1 2.8 1 2.7
Disagree 4 11.1 3 8.1
Neutral 12 33.3 17 45.9
Agree 11 30.6 10 27.0
Strongly agree 8 22.2 3 8.1
Medication should weaken anorexic thoughts
Strongly disagree 1 2.8 0 0
Disagree 3 8.3 2 5.4
Neutral 12 33.3 9 24.3
Agree 15 41.7 18 48.6
Strongly agree 5 13.9 6 16.2
More research on drug treatment for anorexia nervosa is needed
Strongly disagree 0 0 1 2.7
Disagree 1 2.8 0 0
Neutral 7 19.4 5 13.5
Agree 14 38.9 13 35.1
Strongly agree 13 36.1 15 40.5
Willingness to take part in research for drug treatment for anorexia nervosa
Strongly disagree 5 13.9 2 5.4
Disagree 7 19.4 6 16.2
Neutral 10 27.8 18 48.6
Agree 8 22.2 7 18.9
Strongly agree 6 16.7 2 5.4
For the exact wording of the questions, see questionnaire 1 and 2 in the appendix of this chapter.
Table 1.
Frequencies and percentages of answers regarding the overall opinion on drug treatment for AN, important
target symptoms, relevance of psychopharmacological research and willingness to take part.
7
Patients’ and Carers’ Perspectives of Psychopharmacological Interventions Targeting…
DOI: http://dx.doi.org/10.5772/intechopen.86083
Patients (N = 36) Carers (N = 37)
Frequency Percent (%) Frequency Percent (%)
Concerns about weight gain during drug treatment
Strongly disagree 0 0 3 8.1
Disagree 1 2.8 10 27.0
Neutral 2 5.6 11 29.7
Agree 9 25.0 6 16.2
Strongly agree 24 66.7 5 13.5
Concerns about appetite increase during drug treatment
Strongly disagree 0 0 2 5.4
Disagree 2 5.6 11 29.7
Neutral 1 2.8 13 35.1
Agree 13 36.1 3 8.1
Strongly agree 20 55.6 4 10.8
Concerns about binge eating during drug treatment
Strongly disagree 1 2.8 1 2.7
Disagree 2 5.6 1 2.7
Neutral 3 8.3 7 18.9
Agree 8 22.2 13 35.1
Strongly agree 22 61.1 10 27.0
Concerns about changes in body shape during drug treatment
Strongly disagree 1 2.8 2 5.4
Disagree 0 0 5 13.5
Neutral 2 5.6 17 45.9
Agree 14 38.9 4 10.8
Strongly agree 19 52.8 4 10.8
Concerns about changes in metabolism during drug treatment
Strongly disagree 0 0 1 2.7
Disagree 1 2.8 4 10.8
Neutral 2 5.6 14 37.8
Agree 11 30.6 9 24.3
Strongly agree 22 61.1 5 13.5
Concerns about mood changes during drug treatment
Strongly disagree 1 2.8 0 0
Disagree 1 2.8 2 5.4
Neutral 4 11.1 6 16.2
Agree 18 50.0 18 48.6
Strongly agree 12 33.3 8 21.6
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Patients (N = 36) Carers (N = 37)
Frequency Percent (%) Frequency Percent (%)
Concerns about tiredness or sleepiness during drug treatment
Strongly disagree 0 0 1 2.7
Disagree 3 8.3 2 5.4
Neutral 8 22.2 8 21.6
Agree 14 38.9 16 43.2
Strongly agree 11 30.6 7 18.9
Concerns about problems with the heart or the heart rhythm
Strongly disagree 1 2.8 0 0
Disagree 1 2.8 0 0
Neutral 10 27.8 3 8.1
Agree 14 38.9 8 21.6
Strongly agree 10 27.8 23 62.2
Concerns about nausea during drug treatment
Strongly disagree 0 0 0 0
Disagree 3 8.3 1 2.7
Neutral 12 33.3 5 13.5
Agree 14 38.9 18 48.6
Strongly agree 7 19.4 10 27.0
Concerns about decreased concentration during drug treatment
Strongly disagree 0 0 0 0
Disagree 0 0 0 0
Neutral 8 22.2 10 27.0
Agree 16 44.4 15 40.5
Strongly agree 12 33.3 10 27.0
Concerns about changes in laboratory parameters during drug treatment
Strongly disagree 1 2.8 1 2.7
Disagree 4 11.1 1 2.7
Neutral 12 33.3 6 16.2
Agree 12 33.3 15 40.5
Strongly agree 7 19.4 11 29.7
Concerns about sleep problems during drug treatment
Strongly disagree 0 0 1 2.7
Disagree 1 2.8 0 0
Neutral 3 8.3 4 10.8
Agree 19 52.8 20 54.1
Strongly agree 12 33.3 10 27.0
For the exact wording of the questions, see questionnaire 1 and 2 in the appendix of this chapter.
Table 2.
Frequencies and percentages of answers regarding the overall opinion on side effects of drug treatment for AN.
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4.2 Patients perspective on medication—not suitable to treat anorexia nervosa
but of concern because of weight gain as a side effect
The most obvious discrepancy within the patients’ answers is that they did not
believe medication could help with AN, and were at the same time concerned about
appetite increase and weight gain as potential side effects of medication. This
finding is of great relevance, as the primary outcome criterion in the majority of
clinical studies in AN is an increase in body weight [10, 11, 20]. However, patients
may not perceive weight gain as the core problem of AN, because—as stated
earlier—self-starvation is their own way to attenuate negative affective states and
aversive emotions [12]. Therefore, drug treatment to gain weight alone cannot be
perceived as a good treatment option from the patients’ perspective.
It is of course necessary for patients with AN to gain weight due to the medical
risk associated with extremely low body weight. However, this weight gain should
be supported by addressing the underlying difficulties of anxiety and anorexic
thoughts.
4.3 Anxiety and anorexic thoughts as outcome parameters for future treatment
studies
Our survey showed that anxiety is an important symptom that patients with AN
and their carers want to be addressed during psychopharmacological therapy. This
is not unexpected, as AN has been found to be closely associated with anxiety
disorders [21].
Therefore, questionnaires for anxiety and depression should be used to measure
the outcome of RCTs in AN. However, there are many different questionnaires
available, which all have their advantages and disadvantages. Thus, the suggestions
below may seem arbitrary, however, we would like to provide the reader with some
specific suggestions as to how anxiety, depression and anorexic psychopathology
can be measured.
The Brief Psychiatric Rating Scale (BPRS) assesses 24 different psychiatric
symptoms, among them anxiety, depression, unusual thought content and emo-
tional withdrawal [22]. The Depression Anxiety Stress Scales (DASS) is an instru-
ment designed to measure the three related negative emotional states of depression,
anxiety and stress [23]. There is a 21-item as well as a 42-item available. Both these
questionnaires could be applied in clinical practice to measure the level of anxiety in
a patient with AN or used in future RCTs to test psychopharmacological therapies
with regard to their effectiveness in reducing anxiety. In children, the Revised
Children’s Anxiety and Depression Scale (RCADS), a 47-item questionnaire that
measures the frequency of various symptoms of anxiety and low mood, may be
used [24]. However, our study sample did not include children and adolescents.
To measure anorexic thoughts, the Yale-Brown-Cornell Eating Disorders Scale
(YBC-EDS) [25], the Eating Disorder Examination-Questionnaire (EDE-Q) [26]
and the Revised Beliefs about Voices Questionnaire (BAVQ-R) [27], could be used.
The YBC-EDS measures core preoccupations and rituals related to eating disorders,
the EDE-Q assesses key behavioural features and associated psychopathology of
eating disorders and the BAVQ-R is a self-reported measure of patients’ beliefs,
emotions and behaviour about auditory hallucinations.
4.4 Information on pharmacological treatments for patients and carers
The fact that a large proportion of patients and carers were neutral about certain
statements regarding psychopharmacological treatment for AN is not surprising, as
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currently no medication is approved for the treatment of AN [10]. Therefore,
clinicians could abstain from using psychopharmacological treatment at all and also
from informing patients about this opportunity. However, there is positive evi-
dence from clinical studies for a few drugs, and clinicians may share the results of
these studies with their patients and carers.
For example, olanzapine was found to be superior to placebo in four published
RCTs [28–31] in AN regarding weight gain. It has also been shown to have a
beneficial influence on anxiety [32, 33] and sleep [34] in patients with psychosis.
Helping with anxiety and sleep were important features of a psychopharmacological
drug for patients with AN in our survey. Thus, the high number of people giving a
neutral answer in our survey may point to the need for more information to be
shared with patients and their carers about the psychopharmacological options.
4.5 Side effects
Most patients had concerns about potential weight gain, increased appetite, and
changes in body shape and metabolism. This is understandable, because these are
AN-related fears.
However, the last three decades have seen substantial scientific efforts to examine
the metabolic side effects of psychopharmacological agents, specifically antipsychotic
agents. Weight gain, high blood glucose levels, impaired insulin sensitivity and
changes in lipid metabolism have been found to be unfavourable [35]. However,
these results were first and foremost obtained in patients with schizophrenia. In
patients with AN, however, we have a diametrically opposite metabolic ‘starting
situation’ compared to patients with schizophrenia, as AN patients are significantly
underweight, are at risk of severe hypoglycaemia and hypertriglyceridemia, and have
been found to have an increased insulin sensitivity [36, 37]. Therefore, the side
effects of certain antipsychotics, including olanzapine which increase blood glucose
levels, lower insulin sensitivity, elevate triglyceride levels and lead to weight gain
[35], do appear to be less problematic in patients with AN.
The evidence from RCTs, however, is insufficient in AN to make firm recom-
mendations; and there are no medications approved for the treatment of AN.
Therefore, the above-mentioned conclusions should be drawn with caution, even
though they may appear obvious.
4.6 Limitations
Our survey has several limitations. First of all, the applied questionnaires were
developed during this QI project and are not established measures for examining
patients’ and carers’ opinions on psychopharmacological treatment. At approxi-
mately halfway through the study, we decided to make some minor amendments to
the questionnaires, which led to constraints in the statistical evaluation of the
survey. Secondly, the sample size of 36 patients and 37 carers is relatively low.
However, we hope that by sharing the questionnaires in this book chapter, other
scientists will use them for their research which will lead to a broader database.
Thirdly, a major shortcoming of this survey is the inclusion of adult patients with
AN only, whereas AN is a disorder that starts in childhood and adolescence.
5. Conclusion
We developed two corresponding questionnaires to survey the perspectives of
people with AN and their carers on psychopharmacological treatment for AN.
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Although most patients did not believe that medication could help with AN, the
majority thought that medication for AN should help with anxiety, concentration,
sleep problems and anorexic thoughts. Most of the carers shared the view that drug
treatment for AN should help with anxiety and anorexic thoughts. Therefore, these
symptoms should be given attention when prescribing psychopharmacological
agents for people with AN or when planning RCTs for AN.
Most patients had concerns about potential weight gain, increased appetite,
changes in body shape and metabolism. However, psychopharmacological drugs
may actually help with metabolic peculiarities in patients with AN, including
hypoglycaemia.
No psychopharmacological treatment is currently approved for AN, and scien-
tific data on effects and side effects in individuals with AN is scarce. Therefore,
although far-reaching conclusions should not be drawn, the available data and
information should be shared with patients and their carers to reach the best
possible decision on whether drugs should be used for the treatment of AN.
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Appendix. Questionnaires
A.1 Questionnaire 1: patient views on medication targeting anorexia
nervosa symptoms
This questionnaire has been created to help develop research around the use of
psychopharmacological medication in anorexia nervosa. Your input will help refine
future research projects. Please answer the questions according to what you think.
Insert own text if required. Thank you for your participation.
Personal information
1. My age Years
2. My gender Female/male/other
3. My current treatment: I am currently treated in the following service (FREED,
Outpatient, Day-care, SEED, Step-up, Inpatient):
4. Duration of my current treatment in the above-mentioned service:
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Duration of illness
5. For how many years have you had anorexia nervosa?
Years
Previous drug treatment for anorexia nervosa
Yes No
6. I have been treated with a psychiatric medication (medication for your mental health).
7. I have been treated with antipsychotic medication (such as olanzapine, quetiapine).
8. I have been treated with antidepressant medication (such as sertraline, fluoxetine).
9. Are you currently taking/have you previously taken prescribed medication
relating to anorexia nervosa? Please specify which.
10. Have you experienced side effects from this medication? Please specify.
11. Do you feel the medication helped?
Opinion about therapeutic effects of a medication for anorexia nervosa
Strongly
disagree
Disagree Neutral Agree Strongly
agree
12. I think a drug could help treat my anorexia
nervosa.
13. I would consider taking medication for
treatment of anorexia nervosa.
14. I don’t want to take any medication.
15. I would take medication if it is recommended
by my therapist or medical doctor.
16. I would like medication to help me with my
anxiety.
17. I would like medication to help me with my
mood.
18. I would like medication to help improve my
concentration.
19. I would like medication to help increase my
appetite.
20. I would like a medication to help improve my
sleep.
21. I would like a medication to help me with
gastrointestinal symptoms such as
constipation.
22. I would like medication to help weaken the
anorexic voice or anorexic thoughts.
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Strongly
disagree
Disagree Neutral Agree Strongly
agree
23. There should be more research on drug
treatments in anorexia nervosa.
24. I would take part in a trial to assist in
research into drug treatment for anorexia
nervosa.
25. In your own words, what else would you like medication to help with in
overcoming anorexia nervosa?
Views on side effects of a medication for anorexia nervosa
Which of the following potential side effects would you be concerned about in
taking a new medication?
Strongly
disagree
Disagree Neutral Agree Strongly
agree
26. Weight gain
27. Appetite increase
28. Binge eating
29. Changes in my body shape
30. My metabolism could change, making it
harder to burn calories
31. Mood changes
32. Tiredness or sleepiness
33. Problems with my heart or heart rhythm.
34. Nausea
35. Decreased concentration
36. Changes in my bloods
37. Sleep problems
38. Changes in the way you think
39. In your own words: What side effect do you fear most?
40. Further comments and suggestions for research around medication targeting
anorexia nervosa symptoms.
Thank you for taking part in this survey and answering the questions.
A.2 Questionnaire 2: carer views on medication targeting anorexia
nervosa symptoms
This questionnaire has been created to help develop research around the use of
psychopharmacological medication in anorexia nervosa. Your input will help refine
future research projects. Please answer the questions according to what you think.
Insert own text if required. Thank you for your participation.
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Personal information
1. My own age Years
2. My own gender Female/male/other
3. Age of my loved one with anorexia nervosa Years
4. Gender of my loved one with anorexia nervosa Female/male/other
5. Current treatment: My loved one is currently receiving eating disorder treat-
ment in the following service (FREED, Outpatient, Day-care, SEED, Step-up,
Inpatient):
6. Duration of my loved one’s current treatment in the above-mentioned service:
Duration of illness
7. For how many years has your loved one had anorexia nervosa?
Years
Previous drug treatment for anorexia nervosa
Yes No
8. My loved one has been treated with medication for their mental health problem.
9. My loved one has been treated with antipsychotic medication (such as olanzapine,
quetiapine).
10. My loved one has been treated with antidepressant medication (such as sertraline,
fluoxetine).
11. Is your loved one currently taking/has your loved one previously taken
prescribed medication relating to anorexia nervosa or other mental health
problems? Please specify which.
12. Has your loved one experienced side effects from this medication? Please
specify.
13. Do you feel the medication helped them?
Opinion about therapeutic effects of a medication for anorexia nervosa
Strongly
disagree
Disagree Neutral Agree Strongly
agree
14. I think medication could help my loved one
with anorexia nervosa.
15. Patients with anorexia nervosa should
consider taking medication for treatment of
anorexia nervosa.
16. I don’t want my loved one to take
medication.
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Strongly
disagree
Disagree Neutral Agree Strongly
agree
17. My loved one should take medication if it is
recommended by a therapist or medical
doctor.
18. I would want any medication to help my
loved one with their anxiety.
19. I would want any medication to help my
loved one with their low mood.
20. I would want any medication to help my
loved one improve their concentration.
21. I would want any medication to help my
loved one increase their appetite.
22. I would want any medication to help my
loved one to sleep better.
23. I would want any medication to help my
loved one with gastrointestinal symptoms
such as constipation.
24. I would want any medication to help weaken
the anorexic voice or anorexic thoughts my
loved one was experiencing.
25. There should be more research on drug
treatments in anorexia nervosa.
26. I would encourage my loved one to take part
in a clinical trial on drug treatment for
anorexia nervosa.
27. In your own words, what else would you like medication to help your loved
one with in overcoming anorexia nervosa?
Views on side effects of a medication for anorexia nervosa
Which of the following potential side effects would you be concerned about, if
your loved one takes medication?
Strongly
disagree
Disagree Neutral Agree Strongly
agree
28. Weight gain
29. Appetite increase
30. Binge eating
31. Changes in body shape
32. The metabolism could change, making it
harder to burn calories
33. Mood changes
34. Tiredness or sleepiness
35. Problems with the heart or heart rhythm.
36. Nausea
37. Decreased concentration
38. Changes in bloods
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Strongly
disagree
Disagree Neutral Agree Strongly
agree
39. Sleep problems
40. Changes in the way they think
41. In your own words: What side effect do you fear most for your loved one?
42. Further comments and suggestions for research around medication targeting
anorexia nervosa symptoms.
Thank you for taking part in this survey and answering the questions.
Author details
Amabel Dessain1*, Jessica Bentley2, Janet Treasure1,2, Ulrike Schmidt1,2
and Hubertus Himmerich1,2
1 South London and Maudsley NHS Foundation Trust, London, UK
2 Department of Psychological Medicine, King’s College London, London, UK
*Address all correspondence to: amabel.dessain@slam.nhs.uk
©2019 TheAuthor(s). Licensee IntechOpen. This chapter is distributed under the terms
of theCreativeCommonsAttribution License (http://creativecommons.org/licenses/
by/3.0),which permits unrestricted use, distribution, and reproduction in anymedium,
provided the original work is properly cited.
17
Patients’ and Carers’ Perspectives of Psychopharmacological Interventions Targeting…
DOI: http://dx.doi.org/10.5772/intechopen.86083
References
[1] American Psychiatric Association.
Diagnostic and Statistical Manual of
Mental Disorders. 5th ed. Arlington, VA:
APA Publishing; 2013
[2] Keski-Rahkonen A, Mustelin L.
Epidemiology of eating disorders in
Europe: Prevalence, incidence,
comorbidity, course, consequences, and
risk factors. Current Opinion in
Psychiatry. 2016;29:340-345. DOI:
10.1097/YCO.0000000000000278
[3] Javaras KN, Runfola CD, Thornton
LM, et al. Sex- and age-specific
incidence of healthcare-register-
recorded eating disorders in the
complete Swedish 1979-2001 birth
cohort. The International Journal of
Eating Disorders. 2015;48:1070-1081.
DOI: 10.1002/eat.22467
[4] Schmidt U, Adan R, Böhm I,
Campbell IC, Dingemans A, Ehrlich S,
et al. Eating disorders: The big issue.
Lancet Psychiatry. 2016;3:313-315. DOI:
10.1016/S2215-0366(16)00081-X
[5] Eddy KT, Tabri N, Thomas JJ,
Murray HB, Keshaviah A, Hastings E,
et al. Recovery from anorexia nervosa
and bulimia nervosa at 22-year follow-
up. Journal of Clinical Psychiatry. 2017;
78:184-189. DOI: 10.4088/
JCP.15m10393
[6]Himmerich H, Hotopf M, Shetty H,
Schmidt U, Treasure J, Hayes RD, et al.
Psychiatric comorbidity as a risk factor
for mortality in people with anorexia
nervosa. European Archives of
Psychiatry and Clinical Neuroscience.
2019;269:351-359. DOI: 10.1007/
s00406-018-0937-8
[7] Rienecke RD. Family-based
treatment of eating disorders in
adolescents: Current insights.
Adolescent Health, Medicine and
Therapeutics. 2017;8:69-79. DOI:
10.2147/AHMT.S115775
[8] Chen EY, Weissman JA, Zeffiro TA,
Yiu A, Eneva KT, Arlt JM, et al. Family-
based therapy for young adults with
anorexia nervosa restores weight. The
International Journal of Eating
Disorders. 2016;49:701-707. DOI:
10.1002/eat.22513
[9] Thuillier J. Ten years which changed
psychiatry. In: Healy D, editor. The
Psychopharmacologists. London:
Arnold; 2000. pp. 543-559
[10]Himmerich H, Treasure J.
Psychopharmacological advances in
eating disorders. Expert Review in
Clinical Pharmacology. 2018;11:95-108.
DOI: 10.1080/17512433.2018.1383895
[11]Miniati M, Mauri M, Ciberti A,
Mariani MG, Marazziti D, Dell’Osso L.
Psychopharmacological options for
adult patients with anorexia nervosa.
CNS Spectrums. 2016;21:134-142. DOI:
10.1017/S1092852914000790
[12] Brockmeyer T, Friederich HC,
Schmidt U. Advances in the treatment
of anorexia nervosa: A review of
established and emerging interventions.
Psychological Medicine. 2018;48:
1228-1256. DOI: 10.1017/
S0033291717002604
[13] Arcelus J, Mitchell AJ, Wales J,
Nielsen S. Mortality rates in patients
with anorexia nervosa and other eating
disorders. A meta-analysis of 36 studies.
Archives of General Psychiatry. 2011;68:
724-731. DOI: 10.1001/
archgenpsychiatry.2011.74
[14]Murray SB, Loeb KL, Le Grange D.
Treatment outcome reporting in
anorexia nervosa: Time for a paradigm
shift? Journal of Eating Disorders. 2018;
6:10. DOI: 10.1186/s40337-018-0195-1
[15] Brockmeyer T, Holtforth MG, Bents
H, Kämmerer A, Herzog W, Friederich
18
Anorexia and Bulimia Nervosa
HC. Starvation and emotion regulation
in anorexia nervosa. Comprehensive
Psychiatry. 2012;53:496-501. DOI:
10.1016/j.comppsych.2011.09.003
[16]Himmerich H, Joaquim M, Bentley
J, Kan C, Dornik J, Treasure J, et al.
Psychopharmacological options for
adult patients with anorexia nervosa:
The patients’ and carers’ perspectives.
CNS Spectrums. 2018;23:251-252. DOI:
10.1017/S1092852917000529
[17] Stübner S, Grohmann R, Schmauß
M. Drug safety in clinical practice—Part
1: Psychopharmacological treatment.
Fortschritte der Neurologie-Psychiatrie.
2012;80:468-480. DOI: 10.1055/s-0032-
1313085
[18] Stübner S, Grohmann R, Schmauß
M. Drug safety in clinical practice—Part
2: Psychopharmacological treatment.
Fortschritte der Neurologie-Psychiatrie.
2013;81:715-727. DOI: 10.1055/s-0033-
1355883
[19] Treasure J, Nazar BP. Interventions
for the carers of patients with eating
disorders. Current Psychiatry Reports.
2016;18:16. DOI: 10.1007/s11920-015-
0652-3
[20]Dold M, Aigner M, Klabunde M,
Treasure J, Kasper S. Second-generation
antipsychotic drugs in anorexia nervosa:
A meta-analysis of randomized
controlled trials. Psychotherapy and
Psychosomatics. 2015;84:110-116. DOI:
10.1159/000369978
[21]Godart NT, Flament MF, Perdereau
F, Jeammet P. Comorbidity between
eating disorders and anxiety disorders:
A review. The International Journal of
Eating Disorders. 2002;32:253-270. DOI:
10.1002/eat.10096
[22]Overall JE, Gorham DR. The brief
psychiatric rating scale. Psychological
Reports. 1962;10:799-812
[23] Brown TA, Chorpita BF, Korotitsch
W, Barlow DH. Psychometric properties
of the depression anxiety stress scales
(DASS) in clinical samples. Behaviour
Research and Therapy. 1997;35:79-89
[24] Chorpita BF, Moffitt CE, Gray J.
Psychometric properties of the revised
child anxiety and depression scale in a
clinical sample. Behaviour Research and
Therapy. 2005;43:309-322. DOI:
10.1016/j.brat.2004.02.004
[25]Mazure CM, Halmi KA, Sunday SR,
Romano SJ, Einhorn AM. The Yale-
Brown-Cornell eating disorder scale:
Development, use, reliability and
validity. Journal of Psychiatric Research.
1994;28:425-445. DOI: 10.1016/
0022-3956(94)90002-7
[26] Luce KH, Crowther JH. The
reliability of the eating disorder
examination-self-report questionnaire
version (EDE-Q). The International
Journal of Eating Disorders. 1999;25:
349-351. DOI: 10.1002/(SICI)
1098-108X(199904)25:3<349::AID-
EAT15>3.0.CO;2-M
[27] Chandwick P, Lees S, Birchwood M.
The revised beliefs about voices
questionnaire (BAVQ-R). The British
Journal of Psychiatry. 2000;177:229-232.
DOI: 10.1192/bjp.177.3.229
[28] Kafantaris V, Leigh E, Hertz S,
Berest A, Schebendach J, Sterling WM,
et al. A placebo-controlled pilot study of
adjunctive olanzapine for adolescents
with anorexia nervosa. Journal of Child
and Adolescent Psychopharmacology.
2011;21:207-212. DOI: 10.1089/
cap.2010.0139
[29] Brambilla F, Garcia CS, Fassino S,
Daga GA, Favaro A, Santonastaso P,
et al. Olanzapine therapy in anorexia
nervosa: Psychobiological effects.
International Clinical
Psychopharmacology. 2007;22:197-204.
DOI: 10.1097/YIC.0b013e328080ca31
19
Patients’ and Carers’ Perspectives of Psychopharmacological Interventions Targeting…
DOI: http://dx.doi.org/10.5772/intechopen.86083
[30] Bissada H, Tasca GA, Barber AM,
Bradwejn J. Olanzapine in the treatment
of low body weight and obsessive
thinking in women with anorexia
nervosa: A randomized, double-blind,
placebo-controlled trial. American
Journal of Psychiatry. 2008;165:
1281-1288. DOI: 10.1176/appi.
ajp.2008.07121900
[31] Attia E, Kaplan AS, Walsh BT,
Gershkovich M, Yilmaz Z, Musante D,
et al. Olanzapine versus placebo for out-
patients with anorexia nervosa.
Psychological Medicine. 2011;41:
2177-2182. DOI: 10.1017/
S0033291711000390
[32] Tollefson GD, Sanger TM. Anxious-
depressive symptoms in schizophrenia:
A new treatment target for
pharmacotherapy? Schizophrenia
Research. 1999;1(35 Suppl):13-21. DOI:
10.1016/S0920-9964(98)00164-9
[33] Temmingh H, Stein DJ. Anxiety in
patients with schizophrenia:
Epidemiology and management. CNS
Drugs. 2015;29:819-832. DOI: 10.1007/
s40263-015-0282-7
[34] Kluge M, Schacht A, Himmerich H,
Rummel-Kluge C, Wehmeier PM, Dalal
M, et al. Olanzapine and clozapine
differently affect sleep in patients with
schizophrenia: Results from a double-
blind, polysomnographic study and
review of the literature. Schizophrenia
Research. 2014;152:255-260. DOI:
10.1016/j.schres.2013.11.009
[35]Himmerich H, Minkwitz J, Kirkby
KC. Weight gain and metabolic changes
during treatment with antipsychotics
and antidepressants. Endocrine,
Metabolic & Immune Disorders Drug
Targets. 2015;15:252-260. DOI: 10.2174/
1871530315666150623092031
[36] Ilyas A, Hübel C, Stahl D, Stadler M,
Ismail K, Breen G, et al. The metabolic
underpinning of eating disorders: A
systematic review and meta-analysis of
insulin sensitivity. Molecular and
Cellular Endocrinology. 2018. DOI:
10.1016/j.mce.2018.10.005
[37]Winston AP. The clinical
biochemistry of anorexia nervosa.
Annals of Clinical Biochemistry. 2012;
49(Pt 2):132-143. DOI: 10.1258/
acb.2011.011185
20
Anorexia and Bulimia Nervosa
